Print
Email
Print Edition StoriesTuesday, November 3, 2009
Personalized cancer therapy firm On-Q-ity lands $21M
By Mass High Tech staff
Funding drugs for rare diseases
MHT's Marc Songini: Technology to keep seniors healthy
MHT's Marc Songini: Researchers focus on macular degeneration
Waltham cancer diagnostics firm On-Q-ity Inc. is taking in $21 million in venture capital funds, led by Mohr Davidow Ventures, with support from Bessemer Ventures, Physic Ventures and Northgate Capital, according to a report posted on website PEHub.com.
As part of the funding, Sue Siegel of Mohr Davidow and Dion Madsen of Physic Ventures will join the On-Q-ity board.
The funding brings to light the role of former Genzyme Genetics president Mara Aspinall, who now serves as CEO of On-Q-ity. According to the report, On-Q-ity formed from the merger of two Mohr Davidow companies — CELLective Diagnostics and The DNA Repair Company — that were unable to secure funding individually; Aspinall joined CELLective earlier this year.
On-Q-ity says on its website that it identifies cancer characteristics of individual patients in order to determine the best treatment to follow. The company’s technology combines DNA repair biomarkers with circulating tumor cell analysis in determining potential treatments.
On-Q-ity was founded earlier this year, according to a state filing, and changed its name in August from Exalan Biosciences Inc.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
